Which blood clot drug costs less for cancer patients? new study digs into the data
NCT ID NCT05643885
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 19 times
Summary
This study looked at insurance records from over 7,300 cancer patients who had a blood clot (VTE) and were treated with either apixaban or low molecular weight heparin (LMWH). The goal was to compare total healthcare costs, including hospital stays, outpatient visits, and pharmacy bills. The study did not test new treatments but instead analyzed existing data to see which drug might be more cost-effective for this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Investigational
New York, New York, 10017, United States
Conditions
Explore the condition pages connected to this study.